Alnylam Pharmaceuticals Inc.'s underwritten public offering of 7.5 million shares at $10.75 apiece sent shares of the Cambridge, Mass.-based biotech surging more than 14 percent Wednesday as investors showed their approval of its pipeline and partnering power.